Mupirocin calcium - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for mupirocin calcium and what is the scope of patent protection?
Mupirocin calcium
is the generic ingredient in two branded drugs marketed by Glaxosmithkline, Alembic, Amneal, Encube, Glenmark Pharms, Padagis Israel, and Sun Pharma Canada, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.Nine suppliers are listed for this compound.
Summary for mupirocin calcium
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 7 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 121 |
| Clinical Trials: | 3 |
| What excipients (inactive ingredients) are in mupirocin calcium? | mupirocin calcium excipients list |
| DailyMed Link: | mupirocin calcium at DailyMed |
Recent Clinical Trials for mupirocin calcium
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Perrigo Company | Phase 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Taro Pharmaceuticals USA | Phase 1 |
Pharmacology for mupirocin calcium
| Drug Class | RNA Synthetase Inhibitor Antibacterial |
| Mechanism of Action | RNA Synthetase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for mupirocin calcium
US Patents and Regulatory Information for mupirocin calcium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213053-001 | Nov 16, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Padagis Israel | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 212465-001 | Aug 3, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glaxosmithkline | BACTROBAN | mupirocin calcium | CREAM;TOPICAL | 050746-001 | Dec 11, 1997 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glenmark Pharms | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 201587-001 | Jan 24, 2013 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Glaxosmithkline | BACTROBAN | mupirocin calcium | OINTMENT;NASAL | 050703-001 | Sep 18, 1995 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for mupirocin calcium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | BACTROBAN | mupirocin calcium | CREAM;TOPICAL | 050746-001 | Dec 11, 1997 | ⤷ Start Trial | ⤷ Start Trial |
| Glaxosmithkline | BACTROBAN | mupirocin calcium | OINTMENT;NASAL | 050703-001 | Sep 18, 1995 | ⤷ Start Trial | ⤷ Start Trial |
| Glaxosmithkline | BACTROBAN | mupirocin calcium | CREAM;TOPICAL | 050746-001 | Dec 11, 1997 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch